{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05230459",
            "orgStudyIdInfo": {
                "id": "LION-CS101"
            },
            "organization": {
                "fullName": "Asklepios Biopharmaceutical, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)",
            "officialTitle": "A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-the-safety-of-ab-previously-lion-in-subjects-with-genetic-confirmation-of"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-27",
            "studyFirstSubmitQcDate": "2022-01-27",
            "studyFirstPostDateStruct": {
                "date": "2022-02-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Asklepios Biopharmaceutical, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)"
        },
        "conditionsModule": {
            "conditions": [
                "Limb Girdle Muscular Dystrophy",
                "Limb-Girdle Muscular Dystrophy Type 2",
                "LGMD2I",
                "Muscular Dystrophy",
                "LGMD2",
                "LGMD",
                "FKRP",
                "FKRP Mutation",
                "Fukutin Related Protein"
            ],
            "keywords": [
                "gene therapy",
                "LGMD2I",
                "LGMD2I/R9",
                "gene augmentation therapy",
                "FKRP",
                "fukutin related protein",
                "FKRP mutation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AB-1003 Cohort 1",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Genetic: AB-1003 dose level 1"
                    ]
                },
                {
                    "label": "AB-1003 Cohort 2",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Genetic: AB-1003 dose level 2"
                    ]
                },
                {
                    "label": "Placebo (Cohorts 1 and 2)",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "AB-1003 dose level 1",
                    "description": "Single intravenous infusion of AB-1003 gene therapy at dose level 1",
                    "armGroupLabels": [
                        "AB-1003 Cohort 1"
                    ]
                },
                {
                    "type": "GENETIC",
                    "name": "AB-1003 dose level 2",
                    "description": "Single intravenous infusion of AB-1003 gene therapy at dose level 2",
                    "armGroupLabels": [
                        "AB-1003 Cohort 2"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Single intravenous infusion of Placebo",
                    "armGroupLabels": [
                        "Placebo (Cohorts 1 and 2)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events",
                    "description": "Treatment Emergent Adverse Events, Serious Adverse Events, Dose Limiting Toxicity",
                    "timeFrame": "0-52 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female subjects aged 18 and 65 years with clinical diagnosis of LGMD2I/R9 and confirmation of FKRP gene mutation.\n2. Ability to ascend 4 stairs between 2.5 and 10 seconds.\n3. Ability to walk/run 10 meters in \\< 30 seconds.\n4. Able to understand and comply with all study procedures.\n5. Sexually active females of childbearing potential and female and male partners of male subjects receiving AB-1003 must use a barrier method of contraception for the first 6 months after dosing.\n\nExclusion Criteria:\n\n1. Significant cardiomyopathy as defined by echocardiogram (left ventricular ejection fraction \\<40%), evidence of conduction defect (increased PR and RR intervals, left bundle branch block and QTcF \\>480m/sec), NYHA Class 3 or 4 heart failure, or MRI gadolinium enhancement evidence of clinically important myocardial fibrosis.\n2. Contraindication to MRI or hypersensitivity to contrast dyes, shellfish or iodine.\n3. Implanted spinal rods, cardiac pacemaker or other implantation that would distort cardiac MRI images.\n4. History of chronic liver disease (e.g. hepatitis, HIV, steatosis) or abnormal liver function (abnormal GGT and/or abnormal total/direct bilirubin and/or AST and ALT \\>2 ULN).\n5. Abnormal renal function (GFR \\< 60 ml/min, using the MDRD equation).\n6. Any life-threatening disease, including malignant neoplasms and medical history or malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).\n7. In the opinion of the investigator, a pre-existing medical condition that predisposes the subject to risks that outweighs the potential benefits.\n8. Requirement for daytime ventilatory support.\n9. Change in glucocorticosteroid treatment within 3 months prior to baseline visit.\n10. Exposure to another investigational drug within 3 months prior to study treatment or any previous treatment with gene therapy.\n11. Ongoing participation in any other therapeutic clinical trial.\n12. Neutralizing antibody titer to AAV9 \u2265 1:5.\n13. Female subjects who are pregnant, plan to become pregnant in the next 12 months, or breastfeeding.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Medical Affairs at AskBio",
                    "role": "CONTACT",
                    "phone": "919-561-6210",
                    "email": "AskFirst@askbio.com"
                },
                {
                    "name": "myTomorrows (see link below in reference section)",
                    "role": "CONTACT"
                }
            ],
            "locations": [
                {
                    "facility": "University of California - Irvine",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92697",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "UCI Alpha Clinic",
                            "role": "CONTACT",
                            "email": "stemcell@uci.edu"
                        },
                        {
                            "name": "Tahseen Mozaffar, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "University of Iowa",
                    "status": "RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ciara Gibbs",
                            "role": "CONTACT",
                            "email": "ciara-gibbs@uiowa.edu"
                        },
                        {
                            "name": "Katherine Mathews, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "University of Kansas Medical Center",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Kansas",
                    "zip": "66160",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andrea Klempnauer",
                            "role": "CONTACT",
                            "email": "atenney@kumc.edu"
                        },
                        {
                            "name": "Jeffrey Statland, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.11417,
                        "lon": -94.62746
                    }
                },
                {
                    "facility": "Kennedy Krieger Institute",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21205",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mary Yep",
                            "role": "CONTACT",
                            "email": "yep@kennedykrieger.org"
                        },
                        {
                            "name": "Doris Leung, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "VCU",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23298",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anarosa Rezeq",
                            "role": "CONTACT",
                            "email": "anarosa.rezeq@vcuhealth.org"
                        },
                        {
                            "name": "Nicholas E Johnson, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                },
                {
                    "facility": "University of Washington Medical Center",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mike Willis",
                            "role": "CONTACT",
                            "email": "mwillis5@uw.edu"
                        },
                        {
                            "name": "B. Jane Distad, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Link to webpage for study and pre-qualification information",
                    "url": "https://mytomorro.ws/lion-101-gov"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009136",
                    "term": "Muscular Dystrophies"
                },
                {
                    "id": "D000049288",
                    "term": "Muscular Dystrophies, Limb-Girdle"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020966",
                    "term": "Muscular Disorders, Atrophic"
                },
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12093",
                    "name": "Muscular Dystrophies",
                    "asFound": "Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26038",
                    "name": "Muscular Dystrophies, Limb-Girdle",
                    "asFound": "Limb Girdle Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4589",
                    "name": "Atrophy",
                    "relevance": "LOW"
                },
                {
                    "id": "M22697",
                    "name": "Muscular Disorders, Atrophic",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T3963",
                    "name": "Muscular Dystrophy",
                    "asFound": "Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3425",
                    "name": "Limb-girdle Muscular Dystrophy",
                    "asFound": "Limb Girdle Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3434",
                    "name": "Limb-girdle Muscular Dystrophy Type 2A",
                    "asFound": "LGMD2",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3439",
                    "name": "Limb-girdle Muscular Dystrophy Type 2I",
                    "asFound": "LGMD2I",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}